An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment

Inclusion Criteria:

• Confirmed diagnosis of Type 3 von Willebrand disease (VWD), based on medical records

• Adequate hematologic, hepatic, and renal function

• Documented and confirmed previous use of SOC prophylactic therapy for VWD (1-3 timesweekly, as per prescribed dose) and anticipation to remain on the same regimenduring the study

• For participants of childbearing potential: agreement to remain abstinent or adhereto the contraception requirements

Exclusion Criteria:

• Inherited or acquired bleeding disorder other than Congenital Type 3 VWD

• History of gastrointestinal bleeding within 18 months prior to enrollment, or anyprevious diagnosis of angiodysplasia

• History of intracranial hemorrhage

• Previous or current treatment for thromboembolic disease or signs of thromboembolicdisease

• Other conditions (e.g., certain autoimmune diseases) that may increase risk ofbleeding or thrombosis

• History of clinically significant hypersensitivity associated with monoclonalantibody therapies or components of the emicizumab injection

• Use of systemic immunomodulators (e.g., interferon) at enrollment or planned useduring the study, with the exception of anti-retroviral therapy